Anti-thrombotic effects of atorvastatin - An effect unrelated to lipid lowering

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 7, Issue 4, 2002, Pages 247-253

  Gaddam, V ^a   Li, D Y ^a   Mehta, J L ^a,b  

^a CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Atorvastatin; Nitric oxide; Thrombosis

Indexed keywords

ATORVASTATIN; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OXIDIZED LOW DENSITY LIPOPROTEIN; FIBRINOLYTIC AGENT; HEPTANOIC ACID DERIVATIVE; PYRROLE DERIVATIVE;

ABDOMINAL AORTA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICOAGULATION; ANTIOXIDANT ACTIVITY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; THROMBOCYTE AGGREGATION INHIBITION; THROMBOGENESIS; THROMBUS; VASODILATATION; WESTERN BLOTTING; ANIMAL; BIOSYNTHESIS; BLOOD; COMPARATIVE STUDY; DRUG EFFECT; METABOLISM; PATHOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT; THROMBOSIS;

ANIMALS; AORTA, ABDOMINAL; FIBRINOLYTIC AGENTS; HEPTANOIC ACIDS; LIPIDS; MALE; NITRIC OXIDE SYNTHASE; OXIDATIVE STRESS; PYRROLES; RATS; RATS, SPRAGUE-DAWLEY; THROMBOSIS;

EID: 0036818207     PISSN: 10742484     EISSN: None     Source Type: Journal    
DOI: 10.1177/107424840200700408     Document Type: Article

References (24)

1. Conti CR, Mehta JL. Acute myocardial ischemia: Role of atherosclerosis, in situ thrombosis, platelet activation, coronary vasospasm, and altered arachidonic acid metabolism. Circulation V84-V95, 1987
2. Lawson DL, Mehta JL, Nichols WW, Mehta P, Donnelly WH. Superoxide radical-mediated endothelial injury and vasoconstriction of rat thoracic aortic rings. J Lab Clin Med 115:541-548, 1990
3. Mehta JL. Endothelium, coronary vasodilation, and organic nitrates. Am Heart J 129:382-391, 1995
4. Rubanyi GM, Vanhoutte PM. Superoxide anions and hyperoxia inactivate endothelium-derived relaxing factor. Am J Physiol 250:H822-H827, 1986
5. Chen LY, Mehta P, Mehta JL. Oxidized-LDL decreases L-arginine uptake and nitric oxide synthase protein expression in human platelets: Relevance in the effect of oxidized-LDL on platelet function. Circulation 93:1740-1746, 1996
6. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: A meta-analysis of randomized controlled trials. JAMA 282:2340-2346, 1999
7. Eisenberg DA. Cholesterol lowering in the management of coronary artery disease: The clinical implications of recent trials. Am J Med 104:2S-5S, 1998
8. Chen LY, Haught WH, Yang BC, Saldeen TGP, Parathasarathy S, Mehta JL. Preservation of endogenous antioxidant activity and inhibition of lipid peroxidation as common mechanisms of anti-atherosclerotic effect of vitamin E, lovastatin and amlodipine. J Am Coll Cardiol 30:569-575, 1997
9. MAAS investigators. Effects of simvastatin on coronary atheroma: The multicenter anti-atheroma study. Lancet 344:633-638, 1994
10. Jukema JW, Bruschke AV, van Boven AJ, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. Circulation 91:2528-2540, 1995
11. Alfon J, Pueyo Palazon C, Royo T, Badimon L. Effects of statins in thrombosis and aortic lesion development in a dyslipemic rabbit model. Thromb Haemost 81:822-827, 1999
12. Lefer DJ, Scalia R, Jones SP, et al. HMG-CoA reductase inhibition protects the diabetic myocardium from ischemia-reperfusion injury. FASEB J 15:1454-1456, 2001
13. Mehta JL, Li DY, Chen HJ, Joseph J, Romeo F. Inhibition of LOX-1 by statins may relate to upregulation of eNOS. Biochem Biophys Res Commun 289:857-861, 2001
14. Li DY, Weng Y, Yang BC, et al. Inhibition of arterial thrombus formation by ApoA1 Milano. Arterioscler Thromb Vasc Biol 19:378-383, 1999
15. Mehta J, Li DY, Mehta JL. Vitamin C and E prolong time to arterial thrombosis in rats. J Nutr 129:109-112, 1999
16. Ahsan CH, Shah A, Ezekowitz M. Acute statin treatment in reducing risk after acute coronary syndrome: The MIRACL (Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering) Trial Curr Opin Cardiol 16: 390-393, 2001
17. Stenestrand U, Wallentin L. Swedish register of cardiac intensive care (RIKS-HIA). Early statin treatment following acute myocardial infarction and 1-year survival. JAMA 285:430-436, 2001
18. Vaughan CJ, Gotto AM Jr, Basson CT. The evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol 35:1-10, 2000
19. Kureishi Y, Luo Z, Shiojima I, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nature Med 6:1004-1010, 2000
20. Li DY, Chen HJ, Mehta JL. Statins inhibit oxidized-LDL-mediated LOX-1 expression, uptake of ox-LDL and reduction in PKB phosphorylation. Cardiovasc Res 52:130-135, 2001
21. Fenton JW 2nd, Shen GX, Minnear FL, et al. Statin drugs and dietary isoprenoids as anti-thrombotic agents. Hematol Oncol Clin North Am 14:483-490, 2000
22. Puccetti L, Bruni F, Bova G, et al. Role of platelets in tissue factor expression by monocytes in normal and hypercholesterolemic subjects. In vitro effect of cerivastatin. Int J Clin Lab Res 30:147-156, 2000
23. Le Quan Sang KH, Levenson J, Megnien JL, Simon A, Devynck MA. Platelet cytosolic calcium and membrane dynamics in patients with primary hypercholesterolemia: Effects of pravastatin. Arterioscler Thromb Vasc Biol 15:759-764, 1995
24. Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 97:1129-1135, 1998